This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
IKBKE / Inhibitor of nuclear factor kappa-B kinase subunit epsilon · IHC design guide
Design Immunohistochemistry for IKBKE
Plan IKBKE IHC-P around cytoplasmic tissue staining (HPA tissue IHC) and the catalog antibody’s 10 μg/mL starting concentration (datasheet A01816). Score glandular and hematopoietic cells separately, and interpret intensity with the reported medium staining–RNA consistency in mind (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
IKBKE Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic staining in most tissues (HPA tissue IHC) | |
| Staining pattern | Glandular and hematopoietic cells: cytoplasmic stain (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6 HIER, heat-mediated (datasheet A01816) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Formaldehyde-fixed paraffin sections (selected-SKU IHC image A01816); keep fixation consistent (standard IHC practice; not target-specific) | |
| Caveat | Staining and RNA show medium consistency (HPA tissue IHC) | |
| Regulation | Tissue-enhanced RNA in lymphoid tissue (HPA RNA) | |
| Isoform / epitope | 2 isoforms; no extracellular domain to target (UniProt) |
Section 1
Recommended IKBKE IHC & IF Protocols
The catalog antibody protocol uses citrate pH 6 retrieval (datasheet: A01816). Three published IKBKE IHC protocols provide additional tissue and staining details (PMC7418810; PMC5243176; PMC5846766).
| Sample | Formaldehyde-fixed, paraffin-embedded human pancreas tissue (datasheet A01816) |
| Fixation | Image formalin-fixed; duration unreported (datasheet A01816); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6 (datasheet A01816); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% serum (datasheet A01816) |
| Primary antibody | Rabbit anti-IKBKE, 10 μg/mL (datasheet A01816) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | IKBKE-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in most tissues. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6 retrieval (datasheet: A01816); it is also reported for pancreatic sections (PMC5243176). EDTA microwave retrieval is reported for ESCC sections (PMC5846766).
Section 2
What Is the Expected IKBKE Staining Pattern?
IKBKE is primarily cytoplasmic: HPA reports cytoplasmic staining in most tissues, and ICC-IF supports cytosolic localisation (HPA). Expect staining in glandular and hematopoietic cells in the listed positive tissues, with intensity varying by tissue and cell type (HPA). Nuclear localisation can occur under specific conditions (UniProt Q14164). IKBKE has no transmembrane segment (UniProt Q14164 topology). HPA rates its tissue IHC evidence Approved, with medium staining–RNA consistency and external verification pending (HPA).
| Distinct cytoplasmic staining in adrenal or breast glandular cells, or bone marrow hematopoietic cells. | This fits the expected compartment and cells: HPA records High staining in each of these tissue–cell combinations (HPA). Score the identified cells and their cytoplasm, since a tissue-wide impression can obscure which cells carry signal (standard IHC practice). Agreement with these examples supports interpretation but does not independently establish antibody specificity; HPA's tissue evidence still awaits external verification (HPA). |
| Predominantly nuclear or membrane-like staining, with little cytoplasmic signal. | An isolated nuclear pattern conflicts with HPA's usual cytoplasmic tissue profile and supported cytosolic ICC-IF location (HPA). Membrane-like staining also lacks support from IKBKE topology, which has no transmembrane segment (UniProt Q14164 topology). Nuclear signal is not automatically artefactual: UniProt describes TOPORS-dependent targeting to PML nuclear bodies after DNA damage (UniProt Q14164). Interpret that exception only when the experimental context supports it. |
| Strong staining in cells outside the expected positive population, while the listed cells remain faint. | For example, HPA records High staining in bone marrow hematopoietic cells, but Low staining in ovarian stromal cells and adipocytes (HPA). A reversed pattern raises concern about cross-reactivity, endogenous detection activity, or cell identification (standard IHC practice). HPA's listed levels describe observed examples, not a rule that every unlisted cell must be negative; compare morphology and controls before calling a new distribution. |
| Diffuse colour covers cells, extracellular spaces, and the slide without a clear cytoplasmic boundary. | That appearance does not reproduce HPA's cellular cytoplasmic profile (HPA). Broad deposit can arise from background binding or detection chemistry, so it should not be scored as IKBKE-positive cells without an interpretable intracellular pattern (standard IHC practice). Inspect the no-primary control and tissue morphology, then compare staining confined to plausible cells with colour spread across unrelated structures. |
| Little or no signal in a selected positive tissue, including its expected cell population. | HPA lists High staining in several candidate positive samples, including adrenal glandular cells and bone marrow hematopoietic cells (HPA). A blank section therefore warrants a run-level check of the antibody and chromogenic detection workflow (standard IHC practice). It does not by itself prove absent IKBKE: HPA calls its tissue IHC Approved but reports only medium staining–RNA consistency and pending external verification (HPA). |
💡Expected IKBKE appearanceCall a convincing positive result cell-associated, predominantly cytoplasmic staining in the listed glandular or hematopoietic cells, potentially High in HPA's specified examples; diffuse deposit or unsupported membrane-like staining is suspect (HPA; UniProt Q14164 topology; standard IHC practice).
| Tissue and cell selection | HPA reports High staining in adrenal, breast, duodenal, epididymal, fallopian-tube and gallbladder glandular cells, and bone marrow hematopoietic cells; endometrial glandular cells are Medium (HPA). HPA lists glial cells in hippocampus and caudate, ovarian stromal cells, and adipocytes as Low (HPA). Choose comparisons by cell population as well as tissue name, and treat those levels as observations rather than guarantees for every section. |
| Compartment and stimulus | Cytoplasmic staining is the usual tissue pattern, and cytosol is the supported ICC-IF location (HPA). UniProt also places IKBKE in the nucleus and PML bodies, with TOPORS-dependent PML targeting after DNA damage, and describes punctate cytoplasmic bodies with TRIM6 coexpression (UniProt Q14164). Those conditional patterns require matching experimental context; routine nuclear or punctate staining alone does not establish the condition. |
| Antibody evidence and isoforms | HPA labels tissue IHC for HPA015788 and CAB025983 Approved, and ICC for CAB025983 Supported (HPA). UniProt lists two IKBKE isoforms (UniProt Q14164). The supplied record gives no epitope positions, so isoform coverage cannot be inferred; verify the selected antibody's stated application and epitope information before interpreting discrepant staining (standard IHC practice). |
| Fixation evidence | Target-specific fixation sensitivity is unreported in the supplied UniProt and HPA records. Their topology, modification sites, and observed tissue staining do not establish how fixation or antigen retrieval affects IKBKE detection (UniProt Q14164; HPA). Record those workflow conditions when comparing sections, without attributing an observed difference to a documented IKBKE fixation effect. |
| Situation | Likely cause | Next action |
|---|---|---|
| The entire section is pale, including expected positive cells. | A detection-run problem is possible; HPA nevertheless records High staining in selected glandular and hematopoietic populations (HPA; standard IHC practice). | Check that a suitable positive section stains in the same run, then review the antibody's IHC validation and the detection reagents (HPA; standard IHC practice). Confirm the intended cells are present before treating an unstained section as biological absence. |
| Colour remains in a no-primary control or coats unrelated tissue structures. | Endogenous activity or nonspecific detection can produce chromogen independently of primary-antibody binding (standard IHC practice). | Review the detection system's endogenous-activity block and background controls, and score only cell-associated staining with plausible cytoplasmic localisation (standard IHC practice; HPA). Do not use widespread colour as evidence for the HPA tissue pattern. |
| Only nuclei stain strongly in an otherwise routine section. | That differs from HPA's predominant cytoplasmic profile, although conditional nuclear and PML-body localisation is reported by UniProt (HPA; UniProt Q14164). | Check morphology and compartment boundaries; assess whether DNA damage and TOPORS-dependent targeting are relevant to this experiment before assigning the nuclear signal to IKBKE (UniProt Q14164; standard IHC practice). |
| Unexpected cells stain more strongly than the HPA-listed target cells. | Cell misidentification, cross-reactivity, or background detection may explain the mismatch (standard IHC practice); HPA levels are tissue–cell observations with medium staining–RNA consistency (HPA). | Recheck cell identity on the counterstained section, compare a listed High population and a listed Low population, and inspect controls before extending the expected pattern to new cells (HPA; standard IHC practice). |
| Two antibodies give different tissue distributions. | HPA lists HPA015788 and CAB025983 as IHC Approved but describes overall tissue staining–RNA consistency as Medium, with external verification pending (HPA). The supplied record does not identify their epitopes. | Compare staining in the same identified cell populations and check each antibody's application and epitope documentation; do not resolve the disagreement by assuming either antibody detects both UniProt isoforms (HPA; UniProt Q14164; standard IHC practice). |
| Can IF/ICC help assess a disputed compartment? | HPA reports supported cytosolic ICC-IF localisation and marks CAB025983 ICC Supported; its imaged cell lines include A-431, U-251MG and U2OS (HPA). | Use that HPA localisation as an independent compartment comparison when interpreting IHC, while recognising that the listed ICC-IF evidence does not establish the staining pattern of every paraffin tissue (HPA). |
Experiment evidence
IHC & IF images showing IKBKE staining
A01816 · IHCImmunohistochemistry Validation of IKK epsilon in Human Pancreas Tissue Immunohistochemical analysis of paraffin-embedded human pancreas tis
A01816 · IFImmunofluorescence Validation of IKK epsilon in HeLa Cells Immunofluorescent analysis of 4% paraformaldehyde-fixed HeLa cells labeling IKK e
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000263528-IKBKE/tissue/cerebral+cortex#imid_7240888
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000263528-IKBKE/tissue/colon#imid_7240806
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000263528-IKBKE/tissue/liver#imid_7240807
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000263528-IKBKE/tissue/kidney#imid_7240808
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB025983; green = IKBKE, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB025983; green = IKBKE, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for IKBKE IHC & IF
🧪Run bone marrow first: hematopoietic cells should stain strongly (HPA: High in bone marrow hematopoietic cells). HPA detects IKBKE in all 45 scored tissues, so there is no HPA-supported negative tissue; use no-primary and isotype controls, and treat unstained stromal cells on the positive slide as background comparators only, not validated IKBKE-negative cells (HPA: no negative tissue rows).
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: None in HPA: IKBKE is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show IKBKE in A-431, U-251MG, U2OS, with annotated localisation: Cytosol (supported) (HPA subcellular).
Technical controls: Include a secondary-only slide and an isotype control matched to the primary antibody’s host species, Ig class, concentration, and monoclonal or polyclonal format; use IKBKE knockout material, if available, as a biological negative (standard IHC practice). In bone marrow, block endogenous peroxidase and assess pigment-related background before scoring chromogenic staining (standard IHC practice).
⚠️Feasibility: The A01816 paraffin-section caption reports heat retrieval in citrate buffer at pH 6 and formaldehyde fixation, but gives no target-specific fixation window or fixation effect; retrieval dependence beyond that example is unreported (A01816 tissue-IHC caption). Frozen-section performance is unreported, while ICC/IF localization images exist and show supported cytosolic staining (HPA subcellular). In bone marrow, blood-derived peroxidase activity can complicate chromogenic interpretation (standard IHC practice).
HPA tissue IHC evidence for IKBKE
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | High | Protein (IHC) | HPA → |
| Endometrium | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: IKBKE is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced IKBKE IHC Tips
Troubleshoot IKBKE staining in paraffin sections by checking retrieval, cell type, compartment and controls before comparing staining intensity across samples.
Which retrieval conditions should I try when IKBKE staining is weak?
Start with heat-mediated citrate retrieval at pH 6 for paraffin sections (datasheet A01816). The selected pancreas example used this retrieval, 10 µg/mL primary antibody overnight at 4°C, and hematoxylin counterstain (datasheet A01816). If staining remains weak, compare a modestly longer heating interval on matched sections while keeping the buffer and antibody concentration fixed (standard IHC practice). Include a no-primary control and inspect tissue morphology, because excessive heating can damage sections or increase nonspecific staining (standard IHC practice). Judge improvement by cytoplasmic staining in the intended cells, rather than by stronger staining across the entire section (HPA: cytoplasmic expression in most tissues; standard IHC practice).
How should I investigate fixation-related loss of IKBKE staining?
Target-specific fixation sensitivity for IKBKE is unknown from the evidence supplied here (evidence limitation). Record fixative, fixation duration, section thickness and processing batch before changing retrieval or antibody concentration (standard IHC practice). Compare matched sections processed with consistent fixation and citrate retrieval at pH 6, then vary one preparation step at a time (datasheet A01816; standard IHC practice). If an archived block stains poorly, test a separately processed control alongside it, since fixation-related epitope masking cannot be diagnosed from a weak signal alone (standard IHC practice). Do not infer fixation tolerance from IKBKE localisation, phosphorylation sites or tissue staining patterns (UniProt Q14164; HPA: tissue IHC profile).
Does nuclear or punctate staining fit known IKBKE localisation?
Expect cytoplasmic staining as the principal pattern in routine tissue IHC (HPA: cytoplasmic expression in most tissues; HPA: cytosol supported). Nuclear localisation is recorded for IKBKE, including TOPORS-dependent targeting to PML bodies after DNA damage, so a nuclear signal needs biological context and antibody controls (UniProt Q14164; PubMed:20188669; standard IHC practice). Punctate cytoplasmic bodies are reported when IKBKE is coexpressed with TRIM6; that observation alone does not establish a diagnostic pattern in paraffin tissue (UniProt Q14164; PubMed:24882218). Score cytoplasmic and nuclear compartments separately, and compare each pattern with a no-primary section and neighbouring intact cells (standard IHC practice).
Can this antibody distinguish IKBKE isoforms or phosphorylation states in sections?
IKBKE has 2 listed isoforms and a protein kinase domain spanning residues 9–315 (UniProt Q14164). The supplied IHC caption gives staining conditions but does not identify the antibody epitope or establish isoform discrimination (datasheet A01816; evidence limitation). IKBKE has annotated phosphorylation at Ser172, Thr501 and Ser664; ordinary total-protein staining should not be interpreted as a readout of any one site without site-specific validation (UniProt Q14164; standard IHC practice). Check the immunogen or epitope documentation before attributing differences between sections to isoforms, and use an independently validated assay if that distinction drives the conclusion (standard IHC practice).
How should I adapt this tissue question to multiplex IF?
Plan IF as a separate optimisation, because the selected antibody evidence describes chromogenic IHC in paraffin sections (datasheet A01816). In bone marrow, pair IKBKE with a hematopoietic cell marker such as CD45 to identify the expected cell population before assigning signal to individual cells (HPA: high in bone marrow hematopoietic cells; standard IF practice). Choose fluorophores after examining unstained tissue autofluorescence, and place the weaker signal in the cleaner spectral channel (standard IF practice). IKBKE has no transmembrane segment and is predominantly cytosolic, so test mild permeabilisation for intracellular antibody access while checking morphology and no-primary controls (UniProt Q14164 topology; HPA: cytosol supported; standard IF practice).
How can I reduce diffuse brown staining without losing IKBKE signal?
First compare the stained section with no-primary and secondary-only controls to separate antibody-associated signal from detection background (standard IHC practice). For an HRP and DAB workflow, block endogenous peroxidase, optimise serum or protein blocking, and wash thoroughly between incubations (standard IHC practice). The selected pancreas example used 10% serum for 1 hour at room temperature and an HRP secondary at 1:250; these are starting conditions for that example, not universal settings (datasheet A01816). If background persists, titrate the primary around the reported 10 µg/mL while retaining citrate retrieval at pH 6 and checking that cytoplasmic contrast improves (datasheet A01816; standard IHC practice).
What should I measure when comparing IKBKE across tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and cytoplasmic compartment before scoring, because the reported tissue pattern is predominantly cytoplasmic (HPA: cytoplasmic expression in most tissues; standard IHC practice). For comparable regions, record the percentage of positive cells and an H-score from 0–300, or count positive cells per mm² when cell density is the outcome (standard IHC practice). Normalise counts to the analysed tissue area or eligible cell count, and apply the same intensity thresholds, section quality rules and exposure conditions across batches (standard IHC practice). Report nuclear staining separately and avoid treating HPA intensity categories as calibrated concentration measurements (UniProt Q14164 localisation; HPA: tissue IHC profile; standard IHC practice).
When should an apparent IKBKE-positive area be treated as artefact?
A credible result should occur in intact cells with a plausible cytoplasmic pattern and persist when compared with appropriate controls (HPA: cytoplasmic expression in most tissues; standard IHC practice). Examine tissue edges, folds and necrotic regions separately, since uneven reagent access or damaged tissue can create misleading brown signal (standard IHC practice). If staining survives omission of the primary antibody, investigate endogenous peroxidase activity or secondary reagent background before calling the area IKBKE-positive (standard IHC practice). Nuclear staining is biologically possible but requires stronger corroboration, and staining in an unexpected cell population should be checked against morphology and an independent marker (UniProt Q14164 localisation; standard IHC practice). HPA reports medium consistency with RNA data and pending external verification, so use its tissue profile as context rather than proof of specificity (HPA: Approved reliability description).
Boster reagents
Best IKBKE / Inhibitor of nuclear factor kappa-B kinase subunit epsilon IHC Antibodies
A01816 has human paraffin-section IHC and HeLa cell IF images; its catalog also lists human and mouse reactivity (A01816: IHC and IF captions; catalog reactivity).
Real IHC data
Anti-IKK epsilon IKBKE Antibody
Cat # A01816
A01816 is the only SKU with a rendered card: its images show IHC in human pancreas paraffin sections and IF in HeLa cells (A01816: IHC and IF captions). M01816 has IHC and ICC/IF in its application list but no IHC or IF image caption, so it has no rendered card (M01816: catalog applications and image alts).
Which to pick: Choose A01816 for tissue IHC: its own caption documents formaldehyde-fixed human pancreas paraffin sections, citrate retrieval at pH 6, and primary antibody at 10 μg/mL (A01816: IHC caption). For IF with image evidence, choose A01816 at 20 μg/mL in paraformaldehyde-fixed HeLa cells; M01816 lists ICC/IF and is monoclonal, but its fixative is unreported and it has no IF image caption (A01816: IF caption; M01816: catalog applications, clone and image alts). For human and mouse reactivity, choose A01816; its IHC and IF image evidence is human only (A01816: catalog reactivity, IHC and IF captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q14164 (IKKE_HUMAN, Inhibitor of nuclear factor kappa-B kinase subunit epsilon).
- Human Protein Atlas. IKBKE tissue IHC expression (reliability: Approved).
- Human Protein Atlas. IKBKE subcellular location (ICC-IF): Localized to the cytosol..
- Human Protein Atlas. IKBKE antibody validation summary (2 antibodies).
- IKBKE, a prognostic factor preferentially expressed in mesenchymal glioblastoma, modulates tumoral immunosuppression through the STAT3/PD‐L1 pathway. Clinical and Translational Medicine 2020 — PMC7418810.
- IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis. Cancer research 2017 — PMC5243176.
- Prognostic significance of preoperative IKBKE expression in esophageal squamous cell carcinoma. OncoTargets and therapy 2018 — PMC5846766.
- Phosphorylation of tumour suppressor Amotl2 by IKBKE kinase promotes YAP1 signalling, enhancing glioblastoma growth. Frontiers in oncology 2026 — PMC13447070.
- PubMed PMID:10421793 — UniProt-cited evidence.
- PubMed PMID:10882136 — UniProt-cited evidence.
- PubMed PMID:8590280 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for IKBKE (Inhibitor of nuclear factor kappa-B kinase subunit epsilon). Expected localisation Cytoplasmic staining in most tissues (HPA tissue IHC). Antigen retrieval: Citrate pH 6 HIER, heat-mediated (datasheet A01816). Validated IHC antibody: A01816 at 10 μg/mL (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections. Protocol steps: 1. Sample: Formaldehyde-fixed, paraffin-embedded human pancreas tissue (datasheet A01816); 2. Fixation: Image formalin-fixed; duration unreported (datasheet A01816); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6 (datasheet A01816); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% serum (datasheet A01816); 8. Primary antibody: Rabbit anti-IKBKE, 10 μg/mL (datasheet A01816); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Formaldehyde-fixed paraffin sections (selected-SKU IHC image A01816); keep fixation consistent (standard IHC practice; not target-specific); Caveat: Staining and RNA show medium consistency (HPA tissue IHC); Isoform / epitope: 2 isoforms; no extracellular domain to target (UniProt); Regulation: Tissue-enhanced RNA in lymphoid tissue (HPA RNA). Evidence: UniProt Q14164, HPA tissue IHC · Approved, HPA ICC-IF · cytosol., Datasheet A01816, PMC7418810, PMC5243176. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/IKBKE/immunohistochemistry-ihc-guide.